{"id":20842,"date":"2023-07-17T11:45:55","date_gmt":"2023-07-17T03:45:55","guid":{"rendered":"https:\/\/tbenews.com\/tbe\/?p=20842"},"modified":"2023-07-17T11:46:23","modified_gmt":"2023-07-17T03:46:23","slug":"snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara","status":"publish","type":"post","link":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/","title":{"rendered":"Snapshot week 29\/2023
Assessment in mice of a recombinant TBE vaccine based on Modified Vaccinia virus Ankara"},"content":{"rendered":"\n

Kubinski et al.
A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection
Front Immunol<\/em>. 2023;14:1182963. doi:10.3389\/fimmu.2023.1182963<\/p>\n\n\n\n

Various TBE vaccines (inactivated whole virus preparations adsorbed to aluminum hydroxide) which are highly effective have been licensed. However, vaccine breakthrough infections are reported in a low percentage of fully vaccinated individuals. Therefore, research on alternative TBE vaccines is ongoing, and recently a recombinant TBE vaccine based on Modified Vaccinia virus Ankara (MVA) has been evaluated for immunogenicity and protectivity in mice. MVA is highly attenuated to human cells, and the safety and immunogenicity of MVA-based vaccines against a variety of viral pathogens has been demonstrated in clinical trials.<\/p>\n\n\n\n

The pre-membrane prM glycoprotein and the glycoprotein E (gE) gene sequences of TBE virus strain Neud\u00f6rfl were introduced into the MVA vector by homologous recombination resulting in MVA-prME. Immunization of mice with MVA-prME (or FSME-IMMUN for control) was well tolerated, and after two injections, neutralizing antibodies were induced (but not after mock immunization with MVA). In addition, T cell response was shown to various peptide pools by IFN-g ELISpot assays.<\/p>\n\n\n\n

After two-fold immunization with MVA-prME (or with FSME-IMMUN), mice were protected against a lethal challenge dose with TBE virus strain Neud\u00f6rfl. All PBS and MVA control mice developed clinical signs and displayed weight loss.<\/p>\n\n\n\n

Vaccination with MVA-prME reduced viral load in the spleen, central nervous system and gastrointestinal tract and prevented pathological alterations after challenge with virus.<\/p>\n\n\n\n

In summary, MVA-prME showed to be a highly promising approach as an alternative TBE vaccine. MVA-prME was well tolerated in mice and induced a strong neutralizing antibody response comparable with the licensed TBE vaccine FSME-IMMUN. In addition, gE-specific CD4+<\/sup> and CD8+<\/sup> T cell responses were induced, which was not observed after immunization with FSME-IMMUN and which correlated with clearance of infection.<\/p>\n<\/span>","protected":false},"excerpt":{"rendered":"

Kubinski et al.A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infectionFront Immunol. 2023;14:1182963. doi:10.3389\/fimmu.2023.1182963 Various TBE vaccines (inactivated whole virus preparations adsorbed to aluminum hydroxide) which are highly effective have been licensed. However, vaccine breakthrough infections are reported in a low percentage of fully vaccinated individuals. Therefore, research on alternative TBE vaccines is ongoing, and recently a recombinant TBE vaccine based on Modified Vaccinia virus Ankara (MVA) has been evaluated for immunogenicity and protectivity in mice. MVA is highly attenuated to human cells, and the safety and immunogenicity of MVA-based vaccines against a variety of viral pathogens has been demonstrated in clinical trials. The pre-membrane prM glycoprotein and the glycoprotein E (gE) gene sequences of TBE virus strain Neud\u00f6rfl were introduced into the MVA vector by homologous recombination resulting in MVA-prME. Immunization of mice with MVA-prME (or FSME-IMMUN for control) was well tolerated, and after two injections, neutralizing antibodies were induced (but not after mock immunization with MVA). In addition, T cell response was shown to various peptide pools by IFN-g ELISpot assays. After two-fold immunization with MVA-prME (or with FSME-IMMUN), mice were protected against a lethal challenge dose with TBE virus strain Neud\u00f6rfl. All PBS and MVA control mice developed clinical signs and displayed weight loss. Vaccination with MVA-prME reduced viral load in the spleen, central nervous system and gastrointestinal tract and prevented pathological alterations after challenge with virus. In summary, MVA-prME showed to be a highly promising approach as an alternative TBE vaccine. MVA-prME was well tolerated in mice and induced a strong neutralizing antibody response comparable with the licensed TBE vaccine FSME-IMMUN. In addition, gE-specific CD4+ and CD8+ T cell responses were induced, which was not observed after immunization with FSME-IMMUN and which correlated with clearance of infection.<\/p>\n","protected":false},"author":1354,"featured_media":12864,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[18],"tags":[454,1023,536,1024,249],"coauthors":[581],"class_list":["post-20842","post","type-post","status-publish","format-standard","has-post-thumbnail","category-snapshot","tag-immunogenicity","tag-modified-vaccinia-virus-ankara","tag-neutralizing-antibodies","tag-t-cells","tag-vaccine"],"yoast_head":"\nSnapshot week 29\/2023 Assessment in mice of a recombinant TBE vaccine based on Modified Vaccinia virus Ankara - TBE Book<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snapshot week 29\/2023 Assessment in mice of a recombinant TBE vaccine based on Modified Vaccinia virus Ankara - TBE Book\" \/>\n<meta property=\"og:description\" content=\"Kubinski et al.A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infectionFront Immunol. 2023;14:1182963. doi:10.3389\/fimmu.2023.1182963 Various TBE vaccines (inactivated whole virus preparations adsorbed to aluminum hydroxide) which are highly effective have been licensed. However, vaccine breakthrough infections are reported in a low percentage of fully vaccinated individuals. Therefore, research on alternative TBE vaccines is ongoing, and recently a recombinant TBE vaccine based on Modified Vaccinia virus Ankara (MVA) has been evaluated for immunogenicity and protectivity in mice. MVA is highly attenuated to human cells, and the safety and immunogenicity of MVA-based vaccines against a variety of viral pathogens has been demonstrated in clinical trials. The pre-membrane prM glycoprotein and the glycoprotein E (gE) gene sequences of TBE virus strain Neud\u00f6rfl were introduced into the MVA vector by homologous recombination resulting in MVA-prME. Immunization of mice with MVA-prME (or FSME-IMMUN for control) was well tolerated, and after two injections, neutralizing antibodies were induced (but not after mock immunization with MVA). In addition, T cell response was shown to various peptide pools by IFN-g ELISpot assays. After two-fold immunization with MVA-prME (or with FSME-IMMUN), mice were protected against a lethal challenge dose with TBE virus strain Neud\u00f6rfl. All PBS and MVA control mice developed clinical signs and displayed weight loss. Vaccination with MVA-prME reduced viral load in the spleen, central nervous system and gastrointestinal tract and prevented pathological alterations after challenge with virus. In summary, MVA-prME showed to be a highly promising approach as an alternative TBE vaccine. MVA-prME was well tolerated in mice and induced a strong neutralizing antibody response comparable with the licensed TBE vaccine FSME-IMMUN. In addition, gE-specific CD4+ and CD8+ T cell responses were induced, which was not observed after immunization with FSME-IMMUN and which correlated with clearance of infection.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/\" \/>\n<meta property=\"og:site_name\" content=\"TBE Book\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-17T03:45:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-17T03:46:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Shaqeez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shaqeez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\\\/\"},\"author\":{\"name\":\"Shaqeez\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2bc2ab1f56f93257537a0ce8de903224\"},\"headline\":\"Snapshot week 29\\\/2023 Assessment in mice of a recombinant TBE vaccine based on Modified Vaccinia virus Ankara\",\"datePublished\":\"2023-07-17T03:45:55+00:00\",\"dateModified\":\"2023-07-17T03:46:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\\\/\"},\"wordCount\":321,\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"keywords\":[\"immunogenicity\",\"Modified Vaccinia virus Ankara\",\"neutralizing antibodies\",\"T cells\",\"vaccine\"],\"articleSection\":[\"Snapshot\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\\\/\",\"name\":\"Snapshot week 29\\\/2023 Assessment in mice of a recombinant TBE vaccine based on Modified Vaccinia virus Ankara - TBE Book\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"datePublished\":\"2023-07-17T03:45:55+00:00\",\"dateModified\":\"2023-07-17T03:46:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"width\":1180,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Snapshot week 29\\\/2023 Assessment in mice of a recombinant TBE vaccine based on Modified Vaccinia virus Ankara\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"name\":\"The TBE Book\",\"description\":\"Tick-borne Encephalitis (TBE)\",\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\",\"name\":\"Global Health Press\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"width\":1000,\"height\":715,\"caption\":\"Global Health Press\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2bc2ab1f56f93257537a0ce8de903224\",\"name\":\"Shaqeez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g2ce4daa834e38f5ff18a9faa82d1596d\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g\",\"caption\":\"Shaqeez\"},\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/author\\\/shaqeez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Snapshot week 29\/2023 Assessment in mice of a recombinant TBE vaccine based on Modified Vaccinia virus Ankara - TBE Book","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/","og_locale":"en_US","og_type":"article","og_title":"Snapshot week 29\/2023 Assessment in mice of a recombinant TBE vaccine based on Modified Vaccinia virus Ankara - TBE Book","og_description":"Kubinski et al.A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infectionFront Immunol. 2023;14:1182963. doi:10.3389\/fimmu.2023.1182963 Various TBE vaccines (inactivated whole virus preparations adsorbed to aluminum hydroxide) which are highly effective have been licensed. However, vaccine breakthrough infections are reported in a low percentage of fully vaccinated individuals. Therefore, research on alternative TBE vaccines is ongoing, and recently a recombinant TBE vaccine based on Modified Vaccinia virus Ankara (MVA) has been evaluated for immunogenicity and protectivity in mice. MVA is highly attenuated to human cells, and the safety and immunogenicity of MVA-based vaccines against a variety of viral pathogens has been demonstrated in clinical trials. The pre-membrane prM glycoprotein and the glycoprotein E (gE) gene sequences of TBE virus strain Neud\u00f6rfl were introduced into the MVA vector by homologous recombination resulting in MVA-prME. Immunization of mice with MVA-prME (or FSME-IMMUN for control) was well tolerated, and after two injections, neutralizing antibodies were induced (but not after mock immunization with MVA). In addition, T cell response was shown to various peptide pools by IFN-g ELISpot assays. After two-fold immunization with MVA-prME (or with FSME-IMMUN), mice were protected against a lethal challenge dose with TBE virus strain Neud\u00f6rfl. All PBS and MVA control mice developed clinical signs and displayed weight loss. Vaccination with MVA-prME reduced viral load in the spleen, central nervous system and gastrointestinal tract and prevented pathological alterations after challenge with virus. In summary, MVA-prME showed to be a highly promising approach as an alternative TBE vaccine. MVA-prME was well tolerated in mice and induced a strong neutralizing antibody response comparable with the licensed TBE vaccine FSME-IMMUN. In addition, gE-specific CD4+ and CD8+ T cell responses were induced, which was not observed after immunization with FSME-IMMUN and which correlated with clearance of infection.","og_url":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/","og_site_name":"TBE Book","article_published_time":"2023-07-17T03:45:55+00:00","article_modified_time":"2023-07-17T03:46:23+00:00","og_image":[{"width":1180,"height":250,"url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","type":"image\/jpeg"}],"author":"Shaqeez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Shaqeez","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/#article","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/"},"author":{"name":"Shaqeez","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2bc2ab1f56f93257537a0ce8de903224"},"headline":"Snapshot week 29\/2023 Assessment in mice of a recombinant TBE vaccine based on Modified Vaccinia virus Ankara","datePublished":"2023-07-17T03:45:55+00:00","dateModified":"2023-07-17T03:46:23+00:00","mainEntityOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/"},"wordCount":321,"publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","keywords":["immunogenicity","Modified Vaccinia virus Ankara","neutralizing antibodies","T cells","vaccine"],"articleSection":["Snapshot"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/","url":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/","name":"Snapshot week 29\/2023 Assessment in mice of a recombinant TBE vaccine based on Modified Vaccinia virus Ankara - TBE Book","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/#primaryimage"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","datePublished":"2023-07-17T03:45:55+00:00","dateModified":"2023-07-17T03:46:23+00:00","breadcrumb":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/#primaryimage","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","width":1180,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-29-2023-assessment-in-mice-of-a-recombinant-tbe-vaccine-based-on-modified-vaccinia-virus-ankara\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tbenews.com\/tbe\/"},{"@type":"ListItem","position":2,"name":"Snapshot week 29\/2023 Assessment in mice of a recombinant TBE vaccine based on Modified Vaccinia virus Ankara"}]},{"@type":"WebSite","@id":"https:\/\/tbenews.com\/tbe\/#website","url":"https:\/\/tbenews.com\/tbe\/","name":"The TBE Book","description":"Tick-borne Encephalitis (TBE)","publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tbenews.com\/tbe\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tbenews.com\/tbe\/#organization","name":"Global Health Press","url":"https:\/\/tbenews.com\/tbe\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","width":1000,"height":715,"caption":"Global Health Press"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2bc2ab1f56f93257537a0ce8de903224","name":"Shaqeez","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g2ce4daa834e38f5ff18a9faa82d1596d","url":"https:\/\/secure.gravatar.com\/avatar\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g","caption":"Shaqeez"},"url":"https:\/\/tbenews.com\/tbe\/author\/shaqeez\/"}]}},"_links":{"self":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/20842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/users\/1354"}],"replies":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/comments?post=20842"}],"version-history":[{"count":2,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/20842\/revisions"}],"predecessor-version":[{"id":20844,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/20842\/revisions\/20844"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media\/12864"}],"wp:attachment":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media?parent=20842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/categories?post=20842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/tags?post=20842"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/coauthors?post=20842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}